Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: icanpickem who started this subject	3/22/2003 5:14:48 PM
From: microcapfun	Read Replies (3) of 3044

MLN02 The Phase II MLN02 trial for Crohn's disease didn't meet its primary endpoint, and the results of the Phase II MLN02 trail for ulcerative colitis - begun Feb. 2001 - have still not been announced. Finally in the Bear Sterns presentation of 9/17/02, it was stated that the company "never considered MLN02 to be a key contributor to MLNM’s top or bottom line growth". Does anyone have reason for any optimism regarding MLN02 or is it appropriate to more or less write it off? I only ask, because MLN02 seems to be MLNM's 3rd most advanced product, not counting Campath.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next